Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D9HX2V
|
|||
| Drug Name |
ET140203
|
|||
| Drug Type |
Cell therapy
|
|||
| Indication | Hepatocellular carcinoma [ICD-11: 2C12.02; ICD-10: C22.0; ICD-9: 155] | Phase 1/2 | [1] | |
| Company |
Eureka Therapeutics
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04502082) An Open-Label, Dose Escalation, Multi-Center Phase I/II Research Trial to Assess the Safety of ET140203 T Cells and Determine the Recommended Phase II Dose (RP2D) in Adults With Advanced Hepatocellular Carcinoma (HCC) (ARYA-1). U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.